TG Therapeutics Breaks Ground With Subcutaneous Ublituximab, Advancing BRIUMVI’s Future
New TG Therapeutics Phase 1 data shows sub‑cutaneous ublituximab (BRIUMVI) is safe, well‑tolerated, and delivers comparable exposure to IV, hinting at a future quarterly dosing and market expansion.
2 minutes to read
